17 hrs ago
U.S. Supreme Court to Review Burden of Proof to Apply in Patent Licensee Challenges
In 2007, the United States Supreme Court ruled that patent licensees could challenge their obligation to pay patent license royalties under a license agreement without first breaching the license agreement by halting royalty payments.
Tue May 21, 2013
Supreme Court to hear another Case Involving Licensees in Good Standing who Challenge Patent Rights
The Supreme Court has granted a writ of certiorari in a license dispute involving giants of the medical device world - Medtronic and Boston Scientific.
Thu May 16, 2013
Federal Circuit Refuses To Enjoin International Arbitration Of Patent Claims
Just after I posted about the awesome power of federal courts to enjoin other cases , the Federal Circuit reminds us the power is not absolute.
Wed May 15, 2013
Harvard Law Professor to Direct New Stanford IP Clinic
Silicon Valley's companies aren't the only ones poaching each other's intellectual property.
The Myriad Case and 'Gene' Patents: Much Ado about Nothing?
The biggest concern of the biotechnology industry caused by the impending Supreme Court decision in the AMP v. Myriad Genetics case is the threat to existing patents having claims to isolated human DNA that a negative decision from the Court could raise.
Relypsa Announces Appointment of John Orwin as Chief Executive Officer
Relypsa, Inc., a biopharmaceutical company advancing lead product candidate, patiromer for the treatment of hyperkalemia, in a pivotal Phase 3 clinical study, announced today the appointment of John Orwin as Chief Executive Officer of Relypsa.
Tue May 14, 2013
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
At the meeting, Genentech medicines will be highlighted in more than 275 abstracts, of which approximately one third were chosen for oral presentations.
FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test ...
SOUTH SAN FRANCISCO, Calif. & NORTHBROOK, Ill. -- -- Genentech, a member of the Roche Group and Astellas Pharma US, Inc.
Genentech wins new Fda Ok for lung cancer drug, diagnostic test
Genentech Inc. won regulatory approval Tuesday to use its cancer drug Tarceva and a companion diagnostic for non-small cell lung cancer patients with a rare gene mutation.
Mon May 13, 2013
Court Report - May 12, 2013
Bristol-Myers Squibb Co. v. Genentech, Inc. et al. 3:13-cv-02045; filed May 3, 2013 in the Northern District of California Declaratory judgment of invalidity, unenforceability, and noninfringement of of U.S. Patent Nos.
Sat May 11, 2013
hey wayne - yet again .....
What if the government could save hundreds of millions of dollars by listing a cheaper drug, shown to be just as effective as the one which costs the PBS more than any other medicine? You won't find out so long as the company that owns both drugs keeps the bargain-priced cousin shut out.
Mon May 06, 2013
Avastin linked to flesh-eating disease, prompting new label warnings
Genentech Inc.'s cancer-fighting Avastin has been linked to 52 cases of flesh-eating disease over 15 years, prompting updated warnings by health authorities.
Sat May 04, 2013
Recent Study: Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013
GlobalData's clinical trial report, "Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013" provides data on the Retinal Vein Occlusion clinical trial scenario.
PhD Biopharma CEOs: Better, Bolder, Or Occasionally Lucky?
For as long as I can remember, it's been fashionable for management consultants to attribute many of the challenges of biopharmaceutical companies to scientists run amuck .
Fri May 03, 2013
Diabetes drug developer NGM Biopharma, led by Genentech vets Levinson ...
Art Levinson is on the board of NGM Biopharmaceuticals, which has raised about $13.5 million in an equity offering.
New market study, "Vasculitis Global Clinical Trials Review, H1, 2013", has been published
GlobalData's clinical trial report, "Vasculitis Global Clinical Trials Review, H1, 2013" provides data on the Vasculitis clinical trial scenario.
Tue Apr 30, 2013
View Press Release
The medicine can be used in children two years of age and older with active disease.
Thu Apr 25, 2013
Silicon Valley's High-Tech Buses: Just Transit? Or Chariots of the oebergeeks?
Genentech employees alight from one of the company's "gene buses" after arriving at work in South San Francisco.